We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+2.42%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$940M
AUM Growth
-$233M
Cap. Flow
-$192M
Cap. Flow %
-20.48%
Top 10 Hldgs %
46.78%
Holding
113
New
30
Increased
18
Reduced
25
Closed
32

Top Buys

Rank Stock Value
1
NVS icon
Novartis
NVS
+$26.6M
2
ELV icon
Elevance Health
ELV
+$26.1M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$16.4M
4
BAX icon
Baxter International
BAX
+$16.3M
5
RDNT icon
RadNet
RDNT
+$14.8M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$30.3M
2
CAH icon
Cardinal Health
CAH
+$29.6M
3
LLY icon
Eli Lilly
LLY
+$29.3M
4
ISRG icon
Intuitive Surgical
ISRG
+$20.9M
5
MRK icon
Merck
MRK
+$19.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
51
PTC Therapeutics
PTCT
$6.15B
$5.1M 0.54%
+100,000
New +$4.99M
ALKS icon
52
Alkermes
ALKS
$8.26B
$4.95M 0.53%
+150,000
New +$4.89M
VKTX icon
53
CALL
Viking Therapeutics
VKTX
$3.94B
$4.83M 0.51%
+200,000
New +$6.32M
DYN icon
54
Dyne Therapeutics
DYN
$4.99B
$4.71M 0.5%
450,000
+300,000
+200% +$4.29M
LH icon
55
Labcorp
LH
$26.1B
$4.65M 0.5%
+20,000
New +$4.85M
BDX icon
56
Becton Dickinson
BDX
$49.4B
$4.58M 0.49%
+20,000
New +$4.64M
BHVN icon
57
Biohaven
BHVN
$2.19B
$4.21M 0.45%
+175,000
New +$6.17M
CRNX icon
58
Crinetics Pharmaceuticals
CRNX
$8.95B
$4.19M 0.45%
125,000
-175,000
-58% -$6.54M
SRRK icon
59
Scholar Rock
SRRK
$6.34B
$4.02M 0.43%
125,000
-250,000
-67% -$9.62M
ALHC icon
60
Alignment Healthcare
ALHC
$2.74B
$3.72M 0.4%
200,000
-300,000
-60% -$4.47M
GMED icon
61
Globus Medical
GMED
$11.4B
$3.66M 0.39%
+50,000
New +$4.13M
BNTX icon
62
BioNTech
BNTX
$23.3B
$3.64M 0.39%
40,000
-60,000
-60% -$6.72M
CPRX
63
DELISTED
Catalyst Pharmaceutical
CPRX
$3.64M 0.39%
150,000
-150,000
-50% -$3.38M
BBIO icon
64
BridgeBio Pharma
BBIO
$16.4B
$3.46M 0.37%
+100,000
New +$3.37M
SANA icon
65
Sana Biotechnology
SANA
$1.13B
$3.36M 0.36%
2,000,000
– –
CI icon
66
Cigna
CI
$72.4B
$3.29M 0.35%
+10,000
New +$3.01M
NRIX icon
67
Nurix Therapeutics
NRIX
$2.69B
$3.27M 0.35%
275,000
+25,000
+10% +$418K
VSTM icon
68
Verastem
VSTM
$638M
$3.02M 0.32%
+500,000
New +$3.06M
OSCR icon
69
Oscar Health
OSCR
$8.63B
$2.62M 0.28%
200,000
-500,000
-71% -$7.42M
RGEN icon
70
Repligen
RGEN
$9.3B
$2.54M 0.27%
20,000
-20,000
-50% -$3.08M
JSPR icon
71
Jasper Therapeutics
JSPR
$29.7M
$2.47M 0.26%
575,000
-75,000
-12% -$499K
ARWR icon
72
Arrowhead Research
ARWR
$12.6B
$2.23M 0.24%
175,000
-100,000
-36% -$1.82M
ATYR
73
aTyr Pharma
ATYR
$52.4M
$2.11M 0.22%
700,000
+325,000
+87% +$1.19M
TERN
74
DELISTED
Terns Pharmaceuticals
TERN
$1.93M 0.21%
700,000
+250,000
+56% +$1.02M
MREO
75
Mereo BioPharma
MREO
$48.8M
$1.8M 0.19%
800,000
-200,000
-20% -$566K
1 2
3
4 5

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q1 2025 Portfolio in Review

As of Q1 2025, Integral Health Asset Management held 113 positions worth $940M, down 20% from $1.17B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Integral Health Asset Management withdrew a net $192M in Q1 2025, closing 32 positions and reducing 25 holdings. Its most notable exit was Centene, an estimated $30.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier.

Against the trend, Integral Health Asset Management opened a new position in Novartis worth $27.9M.

  • Integral Health Asset Management's largest Q1 2025 buy was Novartis: 250,000 shares worth $27.9M.
  • Integral Health Asset Management added most to Mineralys Therapeutics in Q1 2025, an estimated $16.4M increase.
  • Integral Health Asset Management's biggest Q1 2025 reduction was CVS Health, cutting an estimated $18M.
  • Integral Health Asset Management fully exited Centene in Q1 2025, selling an estimated $30.3M.
  • Integral Health Asset Management's ten largest holdings make up 47% of its $940M portfolio in Q1 2025.
  • Integral Health Asset Management opened 30 new positions and closed 32 in Q1 2025.
  • Integral Health Asset Management's portfolio value fell 20% quarter-over-quarter to $940M.

Based on Integral Health Asset Management's 13F filing for Q1 2025, filed 15 May 2025.